Cure My Disease

Don't miss your cure!

 Log in / Sign up

New scan could spot hidden cancer left behind after liver surgery

NCT ID NCT07704216

Knowledge-focused Sponsor: Second Affiliated Hospital of Xi'an Jiaotong University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 15, 2026 · Last updated Jul 16, 2026 · Updated 1 time

Summary

This study investigates whether a special 3D MRI scan, called magnetic resonance elastography (3D-MRE), can detect microscopic tumor remnants at the surgical margin after liver cancer removal. Current methods only examine the removed tissue, not the remaining liver. Researchers will compare scan results with standard pathology and track patients for recurrence. If accurate, this non-invasive approach could improve post-surgery monitoring and help guide treatment decisions.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Three-Dimensional Magnetic Resonance Elastography (3D-MRE) imaging scan
What this could lead to
If successful, this scan could help doctors identify patients at high risk of cancer returning after liver surgery, allowing for earlier intervention.
What could go wrong
This is an early-stage observational study with 150 participants, so results may not apply to all liver cancer patients. The scan's accuracy may be limited, and it is not a treatment itself.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 150 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Aug 2026

An estimate. Start dates often move.

Expected to finish

Oct 2031

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

This study will enroll adult patients with primary or metastatic liver cancer, including hepatocellular carcinoma, intrahepatic cholangiocarcinoma, or liver metastases (e.g., from colorectal cancer), who undergo curative-intent hepatectomy at the Second Affiliated Hospital of Xi'an Jiaotong University. Eligible patients will undergo postoperative 3D-MRE examination of the remnant liver and be followed to assess pathological resection margin status and subsequent tumor recurrence. Patients will be consecutively recruited from the hepatobiliary surgery department of the study center.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18-80 years * Pathologically confirmed diagnosis of hepatocellular carcinoma, intrahepatic cholangiocarcinoma, or liver metastasis (e.g., from colorectal cancer) * Underwent curative-intent hepatectomy with available postoperative pathological resection margin assessment * Child-Pugh class A or B liver function (for patients with primary liver cancer) * Able to undergo 3D-MRE examination at postoperative day 7-14 * Provision of signed and dated informed consent Exclusion Criteria: * Contraindication to MRI (e.g., non-MRI-compatible implants, severe claustrophobia) * Palliative or non-curative surgery (R2 resection) * Presence of unresectable extrahepatic disease at the time of surgery * Reoperation or unplanned return to surgery within 14 days after the initial hepatectomy * Severe postoperative complications precluding MRI examination at postoperative day 7-14 (e.g., unstable vital signs, need for intensive care) * Death within 14 days after surgery from non-tumor-related causes * Prior history of liver resection or liver transplantation * Pregnant or breastfeeding women * Anticipated poor compliance with postoperative MRE examination or follow-up

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Colorectal cancer liver metastasis are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cholangiocarcinoma hepatocellular carcinoma intrahepatic cholangiocarcinoma metastasis from malignant tumor of colon

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hepato-cellular carcinoma Intrahepatic bile duct carcinoma Metastatic hepatocellular carcinoma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.